This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Short-acting insulin

Authoring team

Replaced by insulin analogues as the quickest acting insulins.

Often known as soluble or ‘regular’ or 'neutral' insulin.

Some features of short-acting or neutral insulins include:

  • peak 2-6 hours after subcutaneous injection
  • tendency to form hexamers in the insulin vials - these dissociate slowly leading to reduction in absorption rate
  • onset of action 30–60 mins
  • peak 2–4 hours
  • in some individuals can have an effect 8-12 hours after administration of injection
  • injected 20-30 minutes before a meal
  • may result in postprandial and nocturnal hypoglycaemia because of long-lasting effects
  • in some patients short-acting insulins remain the optimum quick-acting insulin
  • examples Human Actrapid®, Humulin S®, Insuman® Rapid? (also porcine and bovine equivalents of these)
  • note that some of these insulins are also licensed for use in continuous subcutaneous insulin infusion i.e. insulin pumps (1)

Examples include human actrapid.

Reference:

  1. MeRec Bulletin 2007;17(4).
  2. Prescriber 2001;12 (14): 43-50

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.